{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 20 of 169', 'Panel 2 Schedule of trial procedures: screening and initial treatment period (continued)', 'Screening', 'Initial treatment period', 'Visit', '1\u00b9', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11\u00b2', '12\u00b3', 'Week', '-6', '-2', '0', '2', '4', '6', '8', '10', '12', '14', '15', '16', 'Safety assessments (Sections 10.4 and 11)', 'Pharmacokinetics', 'X', 'X', 'X', 'X\u00b2', 'X', 'ADA', 'X', 'X', 'X', 'Adverse events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Other assessments (Section 10.5)', 'Skin swabs (S. aureus)', 'X', 'X', 'Skin swabs (microbiome)11', 'X', 'X', 'X', 'Serum biomarkers (small panel)', 'X', 'X', 'X', 'X', 'Serum biomarkers (large panel)11', 'X', 'X', 'X', 'X', 'Skin biopsies\u00b91', 'X12', 'X', 'Photography11', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '1) For subjects who do not require a wash-out, visits 1 and 2 will be combined and screening will be reduced to 2 weeks; hence, these subjects will only attend', 'visit 2 (Week-2) which will include all assessments shown under Week -6. Similarly, for subjects who only require a 2-week wash-out, screening visits 1 and 2', 'will be combined (Week -2). The screening period has a maximum duration of 6 weeks.', '2) At Week 15, subjects will only have a blood sample drawn. No assessments that require trial personnel will be performed. Collection of AEs and reporting of', 'concomitant medication and procedures will occur at the following trial visit.', '3) Assessments performed at Week 16 are also to be done at an early termination visit and at a nominal Week 16 visit, if applicable. See Section 8.5 for further', 'details. All subjects will have a final safety follow-up (FU1) 16 weeks after the last dose of IMP, except subjects who enter the long-term extension trial', '(conducted under a separate protocol [LP0162-1337, ECZTEND]). Subjects may enter ECZTEND at any time during the safety follow-up period (see', 'Section 7.1). An end of treatment form and end of trial form must be completed in the eCRF for all subjects assigned treatment.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 21 of 169', '4) Additional informed consents are required for participation in (i) the exploratory component involving microbiome skin swab, large biomarker panel, and skin', 'biopsy, and (ii) the photograph component (selected trial sites only).', '5) Subjects who are eligible for home-use during open-label treatment will have to provide additional informed consent before the training at the site', '(Section 9.2); home-use will only commence after proper training of the subject or caregiver (at 3 dosing visits after the additional consent has been obtained)', 'and after 3 doses of open-label tralokinumab administered at the trial site, i.e., starting no earlier than Week 22, depending on when the subject transfers to', 'open-label treatment (selected countries only).', '6) All subjects must use an emollient twice daily (or more, as needed) for at least 14 days before randomisation and must continue this treatment', 'throughout', 'the', 'trial.', '7) Subjects who achieve a clinical response (IGA 0/1 or EASI75) at Week 16 will be re-randomised into the maintenance period and then receive the first', 'injections of maintenance treatment (Panel 3). Subjects that do not achieve clinical response at Week 16 will be transferred to open-label tralokinumab 300 mg', 'Q2W treatment with optional use of TCS and then receive the first injections of open-label treatment (Panel 4).', '8) For the first 3 IMP dosing visits in both the initial and open-label treatment period, subjects will be monitored after IMP administration for immediate drug', 'reactions for a minimum of 2 hours with vital signs taken every 30 minutes or until stable, whichever is later (Section 9.2).', '9)', 'The eDiary consists of (i) Eczema-related Sleep NRS, (ii) Worst Daily Pruritus NRS, (iii) Average Daily Pruritus NRS, (iv) PGI-B, and (v) PGI-S. The eDiary', 'will be completed daily from Week -2 to Week 52.', '10) IgE not assessed at screening.', '11) Optional, selected trial sites only.', '12) At baseline, a total of 4 skin biopsies will be taken (2 from lesional skin, 2 from non-lesional skin) at an anatomically similar site.', 'ADA, anti-drug antibodies; Bcg, background; BSA, body surface area; C-SSRS, Columbia-Suicide Severity Rating Scale; DLQI, Dermatology Life Quality Index;', 'EASI, Eczema Area and Severity Index; EASI75, at least 75% reduction in EASI score; ECG, electrocardiogram; eDiary, electronic diary; EQ-5D-5L, EuroQoL', \"5-Dimension Health Questionnaire 5 Level; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator's Global Assessment; IgE, immunoglobulin E;\", 'IMP, investigational medicinal product; NA, not applicable; NRS, numeric rating scale; PGI-B, Patient Global Impression of Bother; PGI-S, Patient Global', 'Impression of Severity; POEM, Patient Oriented Eczema Measure; Q2W, every 2 weeks; SCORAD, Scoring Atopic Dermatitis; SF-36, 36-Item Short Form', 'Health', 'Survey; TSQM, Treatment Satisfaction Questionnaire for Medication; WPAI-GH, Work Productivity and Activity Impairment -', 'General', 'Health.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}